{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010438","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.968414+00:00","generated_at":"2026-06-17T07:57:33.324116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncocyte reports FY2022 revenue $5.6M (-27%); plans to extend 10-K filing","bullets":["FY2022 revenue $5.6M (down 27% YoY); Q4 revenue $1.1M (down 69% YoY).","DetermaRx revenue FY2022 $3.6M (+47% YoY); Q4 $0.8M (+3% YoY).","Consolidated operating expenses $69.0M including $44.6M impairment loss; continuing ops revenue $1.0M.","Plans to file Form 12b-25 to extend 10-K deadline to April 17, 2023.","Cost reduction targets quarterly cash burn below $6M in H2 2023 (from $10.5M in H2 2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010438","json":"https://secwatch.observer/filing/0001493152-23-010438.json","markdown":"https://secwatch.observer/filing/0001493152-23-010438.md","text":"https://secwatch.observer/filing/0001493152-23-010438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/0001493152-23-010438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:57:33.324116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcb72c700f081800fe73956552c6402a7c237e1f","claim":"Insight Molecular Diagnostics Inc. reported the full year ended December 31, 2022 results: revenue approximately $1.1 million and $5.6 million, respectively.","evidence_excerpt":"dossier to MolDx in December 2022 2022 Preliminary Financial Results Consolidated revenues for the three and twelve months ended December 31, 2022, were approximately $1.1 million and $5.6 million, respectively, a decrease of 69% compared to fourth quarter 2021 and 27% compared to the full year 2021. Excluding DetermaRx revenue, the continuing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223010438/0001493152-23-010438-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"approximately $1.1 million and $5.6 million, respectively"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}